SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Discovery Laboratories (Nasdaq: DSCO) $0.19. Today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS). The Company submitted a proposal, with a total budget of $2.4 million, for the development of the Company's proprietary capillary aerosol generating (CAG) device technology followed by a Phase 2a clinical trial of aerosolized KL4 surfactant in preterm infants with or at risk for RDS. The Phase I grant provides $580,000 to support development efforts. The Company anticipates the potential awarding of the Phase II grant, up to an additional $1.8 million, following the conclusion of Phase I activities.
Dr. Robert Segal, Discovery Labs' Senior Vice President and the Grant Principal Investigator commented, "We are extremely pleased that the NIH has recognized the importance of our aerosolized KL4 surfactant technology, which has the potential to significantly improve the management of preterm infants with or at risk for RDS and make it possible for many more preterm infants to be treated with surfactant therapy."
What They Do: Discovery Laboratories, Inc. is a biotechnology company developing surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing.
China MediaExpress Holdings (Nasdaq: CCME) $15.25. Today announced that its Board of Directors has approved the implementation of a dividend policy on its common and preferred shares. Pursuant to the policy adopted by the Board, commencing with the six month period ending December 31, 2010, a semi-annual cash dividend of 5% to 10% of CME’s net profit will be paid upon receipt of the related financial statements by the Board. The Company’s Board of Directors will decide the exact payable amount at the corresponding board meetings in light of CME’s cash flows, expected liquidity needs and future corporate strategies.
CME’s Founder & CEO, Zheng Cheng, commented, “Consistent with our commitment to continuously maximize value to our investors, our Board of Directors agreed that with the Company’s exceptional balance sheet and solid free cash flow generation, it is time to recognize the ongoing support of our shareholders. With this payout ratio, we will continue to have the financial flexibility to invest in our high-return, high-growth projects.”
What They Do: CME, through contractual arrangements with Fujian Fenzhong, an entity majority owned by CME’s former majority shareholder, operates the largest television advertising network on inter-city and airport express buses in China.
BioClinica (Nasdaq: BIOC) $4.17. Today announced that GlaxoSmithKline LLC has signed a multi-year enterprise technology agreement to deploy BioClinica’s Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
“GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident,” said Mark Weinstein, CEO of BioClinica. “We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies.”
What They Do: BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
